Search Results


Your search for The ASCO Post Staff,The ASCO Post Staff matches 2767 pages

Showing 1 - 50


Can Treatment With Thiopurines Induce Mutations That May Lead to Pediatric Leukemia Relapse?

Chemotherapy has helped make acute lymphoblastic leukemia (ALL) one of the most survivable childhood cancers. Now, a research team has shown how chemotherapy drugs called thiopurines may lead to mutations that set patients up for disease relapse. These findings were published by Yang et al in...

global cancer care

Study Explores Cost-Effectiveness of CHOP Therapy for Patients With DLBCL in Sub-Saharan Africa

In a clinical trial conducted in Malawi, researchers found that combination chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) provided curative benefit compared to current standard-of care therapy in people diagnosed with diffuse large B-cell lymphoma (DLBCL)—and...

issues in oncology

Survival Trends for Adolescents and Young Adults With Cancer: 40-Year Analysis

Survival rates for adolescents and young adults diagnosed with cancer vary considerably depending on the type of malignancy. A new study published by Riedel Lewis et al in the journal Cancer indicated that survival for multiple cancer types in such patients has improved in recent years, but some...

skin cancer

Pembrolizumab Shows Durable Antitumor Activity in Both Locally Advanced and Recurrent/Metastatic Squamous Cell Carcinomas

The results of the second interim analysis of the KEYNOTE-629 study of pembrolizumab in cutaneous squamous cell carcinoma confirmed durable antitumor activity in both the locally advanced and the recurrent/metastatic settings. Adverse events with pembrolizumab were generally consistent with its...

head and neck cancer
palliative care

Weekly Outpatient Palliative Care Interventions Among Patients With Head and Neck Cancer

Over 90% of patients with head and neck cancer receiving curative-intent chemoradiation therapy found weekly palliative care visits to be a valuable addition to their treatment, a recent study published by Bauman et al in the Journal of Palliative Medicine found. Although palliative care is known...

breast cancer

FDA Approves Pembrolizumab in Combination for High-Risk, Early-Stage Triple-Negative Breast Cancer

On July 26, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for high-risk, early-stage triple-negative breast cancer in combination with chemotherapy as a neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. The FDA also...

Erica Sirrine, PhD, Named Director of Social Work at St. Jude Children’s Research Hospital

Clinical social worker, grief expert, and university dean Erica Sirrine, PhD, has been named Director of Social Work at St. Jude Children’s Research Hospital. For the past 14 years, Dr. Sirrine has worked in higher education, most recently serving as Dean of the College of Behavioral and Social...

Cleveland Clinic Cancer Center Recognizes Shilpa Gupta, MD, and Nima Sharifi, MD

Shilpa Gupta, MD, has been appointed Director of Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic. Her research interests include novel drug development and understanding biomarkers in bladder cancer treatment. Nima ...

Fox Chase Cancer Center Welcomes Peter Abdelmessieh, DO, MSc

Fox Chase Cancer Center recently announced that Peter Abdelmessieh, DO, MSc, will be joining the staff of the Department of Bone Marrow Transplant and Cellular Therapies. Prior to joining Fox Chase, Dr. Abdelmessieh was at Christiana Care Health System in Delaware, where he performed a majority of ...

Sarah Tasian, MD, Appointed Chief of the Section of Hematologic Malignancies, Children’s Hospital of Philadelphia

The Division of Oncology at Children’s Hospital of Philadelphia (CHOP) has appointed Sarah Tasian, MD, as Chief of the Section of Hematologic Malignancies. Dr. Tasian succeeds Richard Aplenc, MD, PhD, MSCE, who served in this role for 13 years. Dr. Tasian will oversee a group of faculty,...

Public Comment on National Coverage Analysis of Screening for Lung Cancer With Low-Dose Computed Tomography

The following letter is adapted from comments made to the Centers for Medicare and Medicaid Services (CMS) by the American College of Radiology, the GO2 Foundation for Lung Cancer, and the Society of Thoracic Surgeons. “The American College of Radiology, the GO2 Foundation for Lung Cancer, and the...

Memorial Sloan Kettering Announces New Initiative to Focus on Lung Cancer Research

Memorial Sloan Kettering Cancer Center (MSK) recently announced a $20 million gift from the Ge Li & Ning Zhao Family Foundation to support lung cancer research and the development of new therapies to treat this disease. Lung cancer is responsible for 25% of all cancer deaths and is the leading...

UCSF Names Ajay Maker, MD, FACS, Chief of Surgical Oncology

Ajay Maker, MD, FACS, has been appointed Chief of the new Division of Surgical Oncology in the Department of Surgery and the Maurice Galante Distinguished Professor in Surgical Oncology at the University of California, San Francisco (UCSF). He will lead surgical oncology services—including breast,...

Sukhmani K. Padda, MD, to Direct Thoracic Medical Oncology at Cedars-Sinai Cancer Center

Thoracic medical oncologist Sukhmani K. Padda, MD, was recently selected to direct Thoracic Medical Oncology at Cedars-Sinai Cancer Center in Los Angeles. Dr. Padda’s appointment, following a national search, reflects her breadth of experience as a clinician and researcher in the field of thoracic...

Oncology Community Mourns the Loss of Investigator Angelo Di Leo, MD, PhD

Oncologist Angelo Di Leo, MD, PhD, recently died after a long struggle with neurodegenerative disease. He was 58 years old. Dr. Di Leo was devoted to breast cancer research for more than 25 years. He first trained with Gianni Bonadonna, MD, in Milan, followed by postdoctoral research at Jules...

breast cancer
myelodysplastic syndromes

FDA Pipeline: Designations for Therapies in Myelodysplastic Syndromes and Triple-Negative Breast Cancer

Recently, the U.S. Food and Drug Administration (FDA) granted special designation status to treatments for myelodysplastic syndromes and advanced triple-negative breast cancer. Breakthrough Therapy Designation for Venetoclax in Combination With Azacitidine for  Myelodysplastic Syndromes Venetoclax...

issues in oncology

Implementation of a Program Providing Free Cancer Screenings, Same-Day Results

Evidence shows that early detection and treatment of cancer can significantly improve health outcomes. However, women in Mississippi—particularly in underserved populations—experience high rates of late-stage cancer diagnoses. A report published by Michelle Williams, PhD, and colleagues in the...


Study Finds the COVID-19 Pandemic Created Significant Disruptions in Cancer Screenings at Federally Qualified Health Centers

A new study has found that the COVID-19 pandemic contributed to significant disruptions in breast, colorectal, and cervical cancer screenings at federally qualified health systems spanning 15 states across the United States. The postponed screenings have created backlogs that systems will need to...

gynecologic cancers

FDA Grants Regular Approval to Pembrolizumab/Lenvatinib for Advanced Endometrial Carcinoma

On July 21, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) in combination with lenvatinib (Lenvima) for patients with advanced endometrial carcinoma that is not microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) who have disease progression...

gynecologic cancers
issues in oncology

Transvaginal Ultrasound Screening Misses More Cases of Endometrial Cancer in Black Women vs White Women

A screening tool used to evaluate the need for endometrial cancer biopsies in women frequently misses the signs of this cancer in Black women, according to a new study published by Kemi M. Doll, MD, and colleagues in JAMA Oncology. Dr. Doll, a gynecologic oncologist at the University of Washington...

breast cancer

Efficacy of Dendritic Cell Vaccines Plus Standard Therapy for Breast Cancer

A report published by Oba et al in the Journal for ImmunoTherapy of Cancer shares new data on combining standard treatment for breast cancer with a particular form of cancer immunotherapy—dendritic cell vaccines. The study is reportedly the first to demonstrate that in situ dendritic cell vaccines...

lung cancer

Study Identifies MET Amplification as a Driver for Some Non–Small Cell Lung Cancers

A study published by D. Ross Camidge, MD, PhD, and colleagues in the Journal of Thoracic Oncology has helped to define MET amplification as a rare but potentially actionable driver for non–small cell lung cancer (NSCLC). Dr. Camidge said many of the major developments in the treatment of NSCLC have ...

gastrointestinal cancer

Atezolizumab Plus Bevacizumab in Malignant Peritoneal Mesothelioma

A phase II study published by Kanwal Raghav, MBBS, MD, and colleagues in Cancer Discovery found that combination treatment with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab was well tolerated and resulted in a 40% objective response rate in patients with advanced malignant...

breast cancer
cost of care

Study Estimates Costs Associated With Metastatic Breast Cancer Treatment May Increase Substantially in the Coming Decade

A study from the UNC Center for Health Promotion and Disease Prevention (HPDP) estimates that annual costs associated with metastatic breast cancer treatment among women in the United States will total $152.4 billion in 2030—nearly two and a half times the estimate for 2015 costs—due to an increase ...

hematologic malignancies

FDA Approves Belumosudil for Chronic Graft-vs-Host Disease

On July 16, the U.S. Food and Drug Administration (FDA) approved belumosudil (Rezurock), a kinase inhibitor, for adult and pediatric patients aged 12 years and older with chronic graft-vs-host disease after failure of at least two prior lines of systemic therapy. KD025-213 Efficacy was evaluated in ...

breast cancer

Terry P. Mamounas, MD, MPH, on Breast Cancer: Extended Aromatase Inhibitor Therapy

Terry P. Mamounas, MD, MPH, of the University of Florida Health Cancer Center, discusses results from the NRG Oncology/NSABP B-42 study, which examined the Breast Cancer Index and its ability to predict whether extended treatment with letrozole benefits patients with hormone receptor–positive...

skin cancer

Study Identifies Gut Microbes Associated With Combination Immunotherapy Response and Adverse Events

Researchers have found that specific intestinal microbiota signatures may correlate with high-grade adverse events and response to combined CTLA-4 and PD-1 blockade treatment. The study, published by Andrews et al in Nature Medicine, also identified a potential new strategy to treat toxicity—while...

breast cancer

Melinda L. Telli, MD, on Breast Cancer: Neoadjuvant Talazoparib for Early HER2-Negative Disease

Melinda L. Telli, MD, of Stanford University, discusses results of a phase II study on neoadjuvant talazoparib in germline BRCA1/2 mutation–positive, early HER2-negative breast cancer. In this setting, talazoparib monotherapy was active and yielded pathologic complete response rates comparable to...


Majority of Patients With Cancer Achieve Immune Response After COVID-19 Vaccination

In a U.S. and Swiss study, nearly all patients with cancer developed an immune response to COVID-19 mRNA vaccines 3 to 4 weeks after receiving their second dose. However, a small group of the patients exhibited no response, raising questions about how their protection against the virus will be...

cns cancers

Study Explores Ketogenic Diet and Intermittent Fasting in Patients With Brain Cancer

More research into the efficacy of a modified ketogenic diet may be beneficial for people with brain tumors, according to a new study published by Schreck et al in the journal Neurology. The diet, which is high in fat and low in carbohydrates, led to changes in the metabolism in the body and the...

multiple myeloma

Paul G. Richardson, MD, on Multiple Myeloma and COVID-19: An Update

Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses challenges patients with multiple myeloma have faced as a result of the COVID-19 pandemic and the research he and his international colleagues are conducting to better understand these difficulties and improve patient care.

gastrointestinal cancer
issues in oncology

Effect of Obesity on Receipt of Chemotherapy in Patients With Colorectal Cancer

Obese patients with colorectal cancer receive lower cumulative doses of adjuvant chemotherapy relative to their body surface area than nonobese patients, according to results from a large meta-analysis reported by Slawinski et al at the ESMO World Congress on Gastrointestinal Cancer 2021 (Abstract...

issues in oncology

ASCO and COA Jointly Release Oncology Medical Home Standards

Today, ASCO and the Community Oncology Alliance (COA) jointly released new Oncology Medical Home (OMH) standards, which provide a comprehensive roadmap for oncology practices to deliver high-quality, evidence-based cancer care. These standards, which were published by Woofter et al in JCO Oncology...

gastrointestinal cancer

DESTINY-Gastric01 Exploratory Biomarker Analysis Examines Efficacy of Trastuzumab Deruxtecan-nxki Among Patients With HER2-Positive and HER2-Low Gastric Cancer

Trastuzumab deruxtecan-nxki demonstrated clinically meaningful benefit across specific subgroups of patients with HER2-positive and HER2-low advanced gastric cancer, according to findings from a post hoc exploratory biomarker analysis presented by Kohei Shitara, MD, and colleagues at the ESMO World ...

Breast Cancer Expert Joseph A. Sparano, MD, FACP, to Join Mount Sinai Health System

Mount Sinai Health System has recruited an internationally recognized expert in the management of breast cancer and human immunodeficiency virus (HIV)-associated malignancies, Joseph A. Sparano, MD, FACP, as Chief of Hematology and Medical Oncology and Deputy Director of The Tisch Cancer Institute...

Suresh S. Ramalingam, MD, Named New Executive Director at Winship Cancer Institute

Suresh S. Ramalingam, MD, has been named Executive Director of Winship Cancer Institute of Emory University. An internationally renowned thoracic oncologist and physician-scientist, Dr. Ramalingam has served as Winship’s Deputy Director since 2016. He began his new post on July 1. Dr. Ramalingam...


Martin H. Dreyling, MD, PhD, on Follicular Lymphoma: Safety and Efficacy of Tisagenlecleucel

Martin H. Dreyling, MD, PhD, of University Hospital Munich Grosshadern Klinikum, discusses phase II results from the ELARA trial, which suggests tisagenlecleucel may be a promising immunotherapy for adults with relapsed or refractory follicular lymphoma (Abstract S210).

skin cancer

Registry Provides Information on Pediatric Melanoma

Pediatric melanoma is a rare disease, with only around 400 cases diagnosed in the United States every year. To better understand this disease and how best to treat it, St. Jude Children’s Research Hospital scientists created a registry called Molecular Analysis of Childhood MELanocytic Tumors...

prostate cancer

Study Investigates Influence of Race on Receipt of Care for Prostate Cancer

Black men most likely to benefit from advanced prostate cancer therapies are 11% less likely to receive them than non-Black men. This happens despite apparent equal opportunities in obtaining health-care services, a new study focused on American veterans has shown. Disparities Exposed Published by...

multiple myeloma

FDA Approves Daratumumab and Hyaluronidase-fihj With Pomalidomide and Dexamethasone for Pretreated Patients With Multiple Myeloma

On July 9, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least one prior line of therapy including lenalidomide and a...

Sarah Cannon Names Navneet Majhail, MD, MS, FASTCT, Deputy Physician-in-Chief of Blood Cancers

Sarah Cannon, the Cancer Institute of HCA Healthcare, announced that Navneet Majhail, MD, MS, FASTCT, has been named Deputy Physician-in-Chief of Blood Cancers for the Sarah Cannon Transplant and Cellular Therapy Network (formerly the Sarah Cannon Blood Cancer Network). In his role, Dr. Majhail...

New IASLC Leadership to Assume Roles at 2021 World Conference on Lung Cancer

Heather Wakelee, MD, will assume the role of President of the International Association for the Study of Lung Cancer (IASLC) at the upcoming IASLC 2021 World Conference on Lung Cancer Denver, Worldwide Virtual Event (WCLC 2021) on September 8 to 14, 2021. Dr. Wakelee has been President-Elect of...

Julio Aguirre-Ghiso, PhD, to Lead New Cancer Dormancy and Tumor Microenvironment Institute at Albert Einstein Cancer Center

Albert Einstein Cancer Center (AECC), Albert Einstein College of Medicine, and Montefiore Health System have announced that cancer biologist Julio Aguirre-Ghiso, PhD, has been named founding Director of the Cancer Dormancy and Tumor Microenvironment Institute (CDTMI), Director of the Gruss-Lipper...

New Medical Director Named to Lead Clinical Cancer Research

The University of California (UC) Davis Comprehensive Cancer Center has named Edward Kim, MD, PhD, as Medical Director for the Office of Clinical Research. Dr. Kim is a UC Davis Health oncologist and Associate Professor of Internal Medicine who specializes in treating gastrointestinal...

The Wistar Institute Recruits Noam Auslander, PhD, as Assistant Professor

The Wistar Institute, an international biomedical research leader in cancer, immunology, and infectious diseases, recently announced the appointment of Noam Auslander, PhD, as Assistant Professor in the Molecular and Cellular Oncogenesis Program of The Wistar Institute Cancer Center. Dr....

Caryn Lerman, PhD, Elected President of the AACI

Caryn Lerman, PhD, is the new President of the Association of American Cancer Institutes (AACI). Dr. Lerman is Director of the University of Southern California (USC) Norris Comprehensive Cancer Center in Los Angeles and Associate Dean for Cancer Programs and the H. Leslie and Elaine S. Hoffman...

bladder cancer

FDA Grants Regular Approval to Enfortumab Vedotin-ejfv for Locally Advanced or Metastatic Urothelial Cancer

On July 9, 2021, the U.S. Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv (Padcev), a Nectin-4–directed antibody and microtubule inhibitor conjugate, for adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor...

multiple myeloma

Study Finds Response to COVID-19 Vaccination Varies Widely in Patients With Multiple Myeloma

Patients with multiple myeloma had a wide variety of responses to COVID-19 vaccines—in some cases, no detectable response at all—pointing to the need for antibody testing and precautions for these patients after vaccination, according to a study published by Van Oekelen et al in Cancer Cell. Mount...

colorectal cancer

Is There a Link Between Use of Antibiotics and Early-Onset Colorectal Cancer?

Study findings presented by Perrott et al at the ESMO World Congress on Gastrointestinal Cancer (Abstract SO-25) showed that the use of antibiotics may be linked to colon tumor formation across all patient age groups, especially in those younger than 50 years. These results raise fresh concerns...

Annual Report to the Nation: Rapid Decrease in Lung Cancer and Melanoma Deaths Lead Overall Continued Decline in Cancer Death Rate

Overall cancer death rates continue to decline in men and women for all racial and ethnic groups in the United States, according to the latest Annual Report to the Nation on the Status of Cancer. During 2001 to 2018, declines in lung cancer death rates accelerated, and death rates for melanoma...